Skip to main content
BioMarin (UK)

BioMarin (UK) Rating A · Worker

BioMarin is a global biotechnology company that develops and commercialises targeted medicines for rare genetic diseases.

BioMarin (UK) Limited Other London Website ↗

The UK Home Office lists BioMarin (UK) as a licensed sponsor (A-rated, Global Business Mobility: Senior or Specialist Worker and Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. We're showing 4 of their current openings.

Sponsor licence details

Sourced from the UK Home Office register of licensed sponsors.

Licence rating
A
Worker · Active
Licensed
Since at least 2021
Headcount
1001-5000
3,163 total
Open roles
4
Live on SponsorJobs
Sector
Other
Location
London
Visa routes
Global Business Mobility: Senior or Specialist Worker
Skilled Worker

Sponsorship history

Certificates of Sponsorship BioMarin (UK) assigned each year, from Home Office figures released under the Freedom of Information Act.

2021
1–5
2022
0
2023
1–5
2024
0
2025
—

Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.

Licence timeline Pro

Every change we've seen on the Home Office register for BioMarin (UK), and what its recent adverts say about sponsorship.

See this employer's full licence history: when it was licensed, rating and route changes, and when it last offered sponsorship in an advert.

Unlock with Pro

About BioMarin (UK)

BioMarin is a global biotechnology company that focuses on translating genetic discoveries into medicines for people living with genetically defined, rare conditions. Founded in 1997, the company researches, develops, and commercialises therapies for serious and life-threatening diseases.

The company's treatments target conditions such as achondroplasia, severe hemophilia A, and several rare inherited metabolic and lysosomal storage diseases, including phenylketonuria and hypochondroplasia. It works closely with patient communities to develop clinical solutions.

Open roles

4 live positions matched to this sponsor licence.